Interestingly, although it has been suggested that tumors with BRCA mutations are sensitive to PARPis (40, 41), findings from our study indicate that PD-L1 induction PARPis by is not dependent on BRCA status, since similar results were obtained from the human pancreatic cancer cell line SW1990 and mouse pancreatic cancer cell line Pan-02, which have a BRCA1 mutation, as well as the human pancreatic cancer cell line BxPc-3 does not have mutations in either BRCA1 or BRCA2 (https://cancer.sanger.ac.uk/cell_lines/). The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.